The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Checkpoint inhibitors

Checkpoint inhibitors

Immune checkpoint molecules, like CTLA-4 and PD-1/PD-L1, act at different stages of T-cell activation and lead to a dampened T-cell response. In response to a normal immune challenge, this pathway prevents hyperstimulation, while in malignancy this can halt immune responses, enabling unimpeded tumor progression. Checkpoint inhibitors target these molecules to reinstate the immune response. 

| |

All Interventions